Fortress Biotech Inc

Financials

Cash from operating activities -83.68 M-116.54 M-179.4 M-128.22 M-80.19 M-65.78 M -65.78 M Cash from investing activities -7.16 M40.51 M-22.93 M-2.1 M-15 M10.12 M 10.12 M Cash from financing activities 172.41 M148.99 M75.32 M32.74 M70.64 M77.44 M 77.44 M Free cash flow -86.81 M-121.51 M-182.12 M-133.29 M-95.19 M-65.78 M -65.78 M

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

FBIO

Financials

Fortress Biotech Inc

Haberler

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment

Fortress Biotech Stock: The PRV Catalyst That Could Reprice This Microcap (NASDAQ:FBIO)

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

FDA çocuklarda Menkes hastalığı için ilk tedaviyi onayladı

FDA approves first treatment for Menkes disease in children

FDA, Fortress Biotech’un Menkes hastalığı tedavisi için yeni PDUFA tarihi belirledi

FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy

Fortress Biotech, Menkes hastalığı tedavisi için NDA başvurusunu yeniden sundu

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript